Related Experiment Video

Updated: Mar 30, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

Relationships between genetic polymorphisms of E670G in PCSK9 gene and coronary artery disease: a meta-analysis

Dilare Adi1, Xiang Xie1, Fen Liu2

  • 1Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University Urumqi 830054, P. R. China ; Xinjiang Key Laboratory of Cardiovascular Disease Research Urumqi 830054, P. R. China.

International Journal of Clinical and Experimental Medicine
|November 10, 2015
PubMed

Insights

The PCSK9 E670G gene polymorphism is linked to an increased risk of coronary artery disease (CAD). This meta-analysis confirms that carriers of the 670G variant have a higher likelihood of developing CAD.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Molecular Biology

Background:

  • The Proprotein Convertase Subtilisin-like Kexin type 9 (PCSK9) gene plays a role in cholesterol metabolism.
  • The E670G polymorphism in the PCSK9 gene has been investigated for its association with coronary artery disease (CAD).
  • Previous studies on this association have yielded controversial results, necessitating further investigation.

Purpose of the Study:

  • To conduct a meta-analysis evaluating the relationship between the PCSK9 E670G gene polymorphism and the risk of CAD.
  • To consolidate existing evidence and provide a more definitive conclusion on the genetic association.

Main Methods:

  • Systematic literature searches were performed to identify relevant case-control studies without language restrictions.
  • A meta-analysis was conducted using Review Manager software (version 5.2).
  • Statistical analysis included heterogeneity assessment (Cochran's Q, I(2)) and calculation of odds ratios (OR) with 95% confidence intervals (CI) across various genetic models.

Main Results:

  • The meta-analysis included 5 case-control studies with 871 CAD patients and 1144 controls.
  • A significant correlation was found between PCSK9 genetic polymorphisms and an increased risk for CAD across all genetic models analyzed (e.g., allele model OR: 1.56, P < 0.001).
  • Specific results included allele model (OR: 1.56), dominant model (OR: 1.46), recessive model (OR: 3.46), homozygous model (OR: 3.89), and heterozygous model (OR: 1.43), all with statistically significant p-values.

Conclusions:

  • The genetic polymorphism E670G in the PCSK9 gene is implicated in the pathogenesis of CAD.
  • Individuals carrying the 670G allele of the PCSK9 gene exhibit a significantly increased risk of developing CAD.
Abstract

Keywords:
PCSK9coronary artery diseasemeta-analysispolymorphisms

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
77
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
123
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
95